MAPT and Parkinson disease: Some authors have found decreased CSF total tau and phosphotau levels when compared with controls (Mollenhauer et al., 2011; Shi et al., 2011; Kang et al., 2013) and similar levels in PD to PSP, DLBD, and MSA (Mollenhauer et al., 2011), while others found higher CSF tau in DLBD compared with PDD patients (Andersson et al., 2011), and still others higher CSF total tau in MSA than in PD patients (Herbert et al., 2014).